Resilient Biopharma Leadership With Ambrx's Dan O'Connor
Business Of Biotech
00:00
The Impact of Restricted Capital Markets on Cancer Therapeutics
Ambrics has two clinical candidates that are focused on the HER2 receptor. The first more mature program is called Air Act 788, and this is an ADC directed towards her too. We're using something called a conjugation linker to bring chemo therapies here into contact with receptors of cancer cells. In other words, we're deploying chemotherapy without having to put it throughout the body as Scripps has.
Transcript
Play full episode
